4,233 results match your criteria Journal of Thoracic Oncology[Journal]


The Role of Prophylactic Cranial Irradiation in Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

J Thorac Oncol 2019 Mar;14(3):e60-e61

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.018DOI Listing

PCI in Small Cell-Review the Cohorts.

J Thorac Oncol 2019 Mar;14(3):e59-e60

Department of Radiation Oncology and Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.007DOI Listing

Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.

J Thorac Oncol 2019 Mar;14(3):e55-e57

Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.025DOI Listing

Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.

J Thorac Oncol 2019 Mar;14(3):e49-e50

Department of Pneumology, AZ Sint-Blasius Hospital, Dendermonde, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.014DOI Listing

Erratum.

Authors:

J Thorac Oncol 2019 Mar;14(3):560

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.001DOI Listing

Lung Cancer Screening in Never-Smokers.

Authors:
Stephen Lam

J Thorac Oncol 2019 Mar;14(3):336-337

British Columbia Cancer and the University of British Columbia, Vancouver, British Columbia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.019DOI Listing

Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?

J Thorac Oncol 2019 Mar;14(3):332-335

Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.017DOI Listing

Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

J Thorac Oncol 2019 Mar;14(3):328-331

Medical School, Paris-Saclay University, Paris-Sud University, Le Kremlin Bicêtre, France; Drug Development Department (DITEP), Gustave Roussy Institute, Paris Saclay University, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.011DOI Listing

Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?

J Thorac Oncol 2019 Mar;14(3):326-327

Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Centre, GROW School of Oncology and Developmental Biology, Maastricht, Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.016DOI Listing

Outcome of non-small cell lung cancer patients with brain metastases treated with checkpoint inhibitors.

J Thorac Oncol 2019 Feb 16. Epub 2019 Feb 16.

Department of medical oncology, Gustave Roussy Cancer Campus, Institut d'Oncologie Thoracique (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France; Paris-Sud University, Orsay, France.

Introduction: although frequent in non-small cell lung cancer (NSCLC), brain metastases (BM) patients are often excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM outcome in a less selected NSCLC cohort.

Methods: data from consecutive advanced ICI treated NSCLC patients were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.009DOI Listing
February 2019

PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.

J Thorac Oncol 2019 Feb 16. Epub 2019 Feb 16.

Department of Thoracic / Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0432, Houston, Texas, 77030, United States of America. Electronic address:

Introduction: Immune checkpoint blockade (ICB) has revolutionized the treatment of non-small cell lung cancer (NSCLC), but only ∼15% of patients achieve durable benefit. Understanding resistance mechanisms to ICB is pivotal in developing more effective treatment strategies. Recent studies showed human leukocyte antigen (HLA) class I heterozygosity might be important in mediating benefit from ICB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.008DOI Listing
February 2019

Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.

J Thorac Oncol 2019 Feb 15. Epub 2019 Feb 15.

Department of radiation oncology, Jean Bernard center, Inter-regional Institute of Oncology, Le Mans, France.

Background: A multicenter randomized clinical trial in France found an overall survival benefit of web-based patient-reported outcome (PRO)-based surveillance following initial treatment for lung cancer compared with conventional surveillance. The aim of this study was to assess the cost-effectiveness of this PRO-based surveillance in lung cancer patients.

Methods: This medico-economic analysis employed data from the clinical trial, augmented by abstracted chart data and costs of consultations, imaging, transportations, information technology, and treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.005DOI Listing
February 2019
1 Read

Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts.

J Thorac Oncol 2019 Feb 13. Epub 2019 Feb 13.

Department of Cardiothoracic Imaging, Toronto Joint Department of Medical Imaging, University of Toronto, Toronto, Canada.

Hypothesis: We hypothesize that the incidence of screen-detected lung cancer (LC), in participants with previously negative scans, will be highest in the cohort with the highest baseline risk score.

Methods: Individuals with negative baseline screening results from the Princess Margaret International Early Lung Cancer Action Program prior to 2009 underwent low-dose CT rescreening from 2015 to 2018. Individuals were contacted in order of descending risk, as determined by the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial's PLCO 6-year LC risk-prediction model, and then categorized into three risk cohorts according to their baseline risks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.031DOI Listing
February 2019
1 Read

Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death.

J Thorac Oncol 2019 Feb 13. Epub 2019 Feb 13.

Department of Oncology, Georgetown University Medical Center, Washington, DC. Electronic address:

Introduction: Platinum-based chemotherapy remains the standard treatment for patients with small cell lung cancer (SCLC), but the benefit of the treatment is often hampered by rapid development of drug resistance. Thus far, there is no targeted therapy available for SCLC. Over 90% of SCLC tumors harbor mutations in the tumor suppressor gene p53, an important DNA damage checkpoint regulator, and these tumor cells rely predominantly on the checkpoint kinases to control DNA damage response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.028DOI Listing
February 2019
2 Reads

The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.

J Thorac Oncol 2019 Feb 13. Epub 2019 Feb 13.

Section of Medical Oncology, Department of Internal Medicine; Developmental Therapeutics Translational Research Program, Yale Comprehensive Cancer Center, New Haven, Connecticut , USA. Electronic address:

Purpose: To characterize the tumor-infiltrating immune cells population in Kras/p53-driven lung tumors and to evaluate the combinatorial anti-tumor effect with MEK inhibitor (MEKi), trametinib, and immunomodulatory monoclonal antibodies (mAbs) targeting either programmed cell death protein-1 (PD-1) or programmed cell death protein ligand 1 (PD-L1) in vivo.

Experimental Design: Trp53;Kras;Rosa26 (PKL) genetically engineered mice were utilized to develop autochthonous lung tumors with intratracheal delivery of adenoviral Cre recombinase. Using these tumor-bearing lungs, tumor-infiltrating immune cells were characterized by both mass cytometry and flow cytometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.004DOI Listing
February 2019
1 Read

Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors.

J Thorac Oncol 2019 Feb 13. Epub 2019 Feb 13.

Service d'Oncologie Médicale, Groupement Hospitalier Centre, Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France; University of Lyon, Université Lyon 1, France. Electronic address:

Introduction: Metastatic lung carcinoids (MLC) remain poorly characterized and no prognostic stratification exists.

Methods: We conducted a retrospective study including patients with MLC in two European expert centers. The aims were to characterize these, identify prognostic factors of survival, and effectiveness of their treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.002DOI Listing
February 2019
1 Read

Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients with Lung Adenocarcinoma.

J Thorac Oncol 2019 Feb 12. Epub 2019 Feb 12.

Institute of Cancer, Xinqiao Hospital of The Third Military Medical University, Chongqing, 400037, China; Chongqing Key Laboratory of Immunotherapy, Xinqiao Hospital of The Third Military Medical University, Chongqing 400037, China. Electronic address:

Introduction: Whether the efficacy of PD-1/PD-L1 inhibitors declines with senescence remains controversial for lung adenocarcinoma (LUAD). Responsiveness to anti-PD-1/PD-L1 therapy is thought to rely on neoantigen exposure and immune elements in the tumor microenvironment. In this study, we explored the features of the tumor immune microenvironment in elderly patients with treatment-naïve LUAD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.024DOI Listing
February 2019

Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR-TKI therapy: CAURAL brief report.

J Thorac Oncol 2019 Feb 11. Epub 2019 Feb 11.

Thoracic Oncology Program, Vanderbilt University Medical Center, Nashville, TN, USA.

Introduction: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Durvalumab is an anti-PD-L1 monoclonal antibody. The Phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and T790M mutation-positive advanced non-small cell lung cancer (NSCLC) and disease progression following EGFR-TKI therapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193010
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.02.001DOI Listing
February 2019
2 Reads
5.282 Impact Factor

2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.

J Thorac Oncol 2019 Feb 11. Epub 2019 Feb 11.

Centrum für Integrierte Onkologie Köln Bonn am Universitätsklinikum Köln, Köln, Germany.

Small cell lung cancer remains an aggressive, deadly cancer with only modest effect on survival from standard chemotherapy. However, with the advent of immunotherapy and comprehensive genomic and transcriptomic profiling, multiple new targets are showing promise in the clinical arena, and just recently PD-L1 inhibition has been shown to improve the efficacy of standard chemotherapy in extended disease SCLC. Our increasing understanding of the interactions between different pathways will enable more tailored immuno- as well as targeted therapies based on specific biomarkers and rational combinations. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193009
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.01.022DOI Listing
February 2019
2 Reads

Brief report: efficacy of immune checkpoint inhibitors in KRAS-mutant Non-small cell lung cancer (NSCLC).

J Thorac Oncol 2019 Feb 6. Epub 2019 Feb 6.

Aix Marseille University; Assistance Publique Hôpitaux de Marseille. Department of Multidisciplinary Oncology and Therapeutic Innovations. Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm UMR1068, CNRS UMR7258, France.

Introduction: KRAS mutation (KRASm) is the most frequent molecular alteration found in advanced non-small cell lung cancer (NSCLC), is associated with a poor prognosis, without available targeted therapy. Treatment options for NSCLC have been recently enriched by the development of immune checkpoint inhibitors (ICI), and data about its efficacy in patients with KRASm NSCLC are discordant. This study assessed the routine efficacy of ICI in advanced KRASm NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.011DOI Listing
February 2019
2 Reads

Characteristics and outcomes of patients with metastatic KRAS mutant lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.

J Thorac Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Electronic address:

Background: Mutations in the KRAS gene are the most common driver oncogenes present in lung adenocarcinomas. We analyzed the largest multi-institutional database available containing patients with metastatic KRAS mutant lung adenocarcinomas.

Methods: The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional collaboration to study the genomic characteristics of lung adenocarcinomas, treat them with genomically directed therapeutic approaches, and assess their outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.020DOI Listing
February 2019

Surgical resection of small cell lung carcinoma: prognostic factors and the tumor microenvironment.

J Thorac Oncol 2019 Feb 5. Epub 2019 Feb 5.

Georgetown University, Washington DC, U.S.A. Electronic address:

Background: Surgery in small cell lung cancer (SCLC) is limited to very early stages, but several reports suggest a potential broader role. Little is known of the influence of microenvironment on the biology of SCLC.

Methods: We assessed the clinical prognostic factors in a large series of resected SCLC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.019DOI Listing
February 2019
1 Read

Survival after SBRT for Clinically diagnosed or Biopsy-proven Early-stage Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

J Thorac Oncol 2019 Feb 2. Epub 2019 Feb 2.

Division of Surgery, Slingeland Ziekenhuis, Kruisbergseweg 25, 7009 BL, Doetinchem, Gelderland, the Netherlands; Division of Surgery, Radboud University Medical Centre, Geert Grooteplein 10, P.O. Box 9101, 6500 HB, Gelderland, Nijmegen, Gelderland, the Netherlands.

Introduction: SBRT is a promising curative treatment for early-stage NSCLC. IT is unclear if survival outcomes for SBRT are influenced by a lack of pathological confirmation of malignancy and staging of disease in these patients. In this systematic review and meta-analysis we assess survival outcomes after SBRT in studies with patients with clinically diagnosed vs biopsy-proven early-stage NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.035DOI Listing
February 2019
1 Read
5.282 Impact Factor

Proposal for a combined histo-molecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors.

J Thorac Oncol 2019 Feb 2. Epub 2019 Feb 2.

Department of Biochemistry, Unit of Pharmacogenetic and Molecular Oncology, Georges Pompidou European Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France; INSERM UMR-S1147, Paris Sorbonne Cite University, Paris, France.

Introduction: Multiple nodules in lung are diagnosed with an increasing frequency due to high quality CT-scan imaging. In patients suffering from lung cancer, this situation represents up to 10% of operated patients. For clinical management, it is important to classify the disease as intra-pulmonary metastasis or multiple primary lung carcinomas to define TNM classification and optimize therapeutic options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.017DOI Listing
February 2019
1 Read

Case Report: Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.

J Thorac Oncol 2019 Jan 31. Epub 2019 Jan 31.

Department of Respiratory Diseases and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.015DOI Listing
January 2019
1 Read

Health-Related Quality of Life in KEYNOTE-010: a Phase 2/3 Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, PD-L1-Expressing NSCLC.

J Thorac Oncol 2019 Jan 31. Epub 2019 Jan 31.

Yale School of Medicine, New Haven, CT, USA.

Background: In the phase 2/3 KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death 1 ligand 1 (PD-L1)-expressing (tumor proportion score [TPS] ≥1%), advanced non-small-cell lung cancer (NSCLC). Health-related quality of life (HRQoL) results are reported here. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193009
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.01.016DOI Listing
January 2019
3 Reads

Survival with Parenchymal and Pleural Invasion of Non-small-cell Lung Cancers less than 30 mm.

J Thorac Oncol 2019 Jan 24. Epub 2019 Jan 24.

Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Purpose: To determine long-term survival of visceral pleural invasion (VPI) and parenchymal (PAI: angiolymphatic, vascular) invasion on survival of non-small-cell-lung-cancers (NSCLCs), less than 30 mm in maximum diameter.

Methods: Kaplan-Meier survival for NSCLCs, with and without VPI and/or PAI were determined for a prospective cohort of screening participants, stratified by pathologic tumor size (≤10mm, 11-20mm, and 21-30mm) and nodule consistency. Log-rank test statistics were calculated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.013DOI Listing
January 2019
2 Reads

Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma.

J Thorac Oncol 2019 Feb;14(2):e42-e44

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183338
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.10.149DOI Listing
February 2019
3 Reads
5.282 Impact Factor

Refractory Severe Esophagitis During Durvalumab Therapy in a Patient With Locally Advanced NSCLC.

J Thorac Oncol 2019 Feb;14(2):e40-e42

Department of Respiratory Medicine, Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.153DOI Listing
February 2019

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.

J Thorac Oncol 2019 Feb;14(2):e34-e36

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.157DOI Listing
February 2019
1 Read

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

J Thorac Oncol 2019 Feb;14(2):e29-e30

City of Hope Comprehensive Cancer Center, Duarte, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.169DOI Listing
February 2019

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.

J Thorac Oncol 2019 Feb;14(2):e27-e29

Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.160DOI Listing
February 2019

Responsiveness to Full-Dose Afatinib in a Patient With Lung Adenocarcinoma Harboring EGFR S768I and V769L Mutations.

J Thorac Oncol 2019 Feb;14(2):e25-e27

Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.165DOI Listing
February 2019

Erratum.

Authors:

J Thorac Oncol 2019 Feb;14(2):314

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.010DOI Listing
February 2019

Erratum.

Authors:

J Thorac Oncol 2019 Feb;14(2):314

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.015DOI Listing
February 2019

Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story.

J Thorac Oncol 2019 Feb;14(2):160-162

David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.009DOI Listing
February 2019

Management of the Brain in Small Cell Lung Cancer: Are Patients Paying a Lot Now Instead of a Little Later?

J Thorac Oncol 2019 Feb;14(2):153-156

Department of Radiation Oncology, State University of New York Upstate Medical University, Syracuse, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.008DOI Listing
February 2019

Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small-Cell Lung Cancer.

J Thorac Oncol 2019 Jan 21. Epub 2019 Jan 21.

Washington University School of Medicine, 1 Brookings Dr, St. Louis, MO 63130, USA.

Introduction: This Phase II study evaluated the efficacy and safety of the pan-cyclin-dependent kinase inhibitor roniciclib with platinum-based chemotherapy in patients with extensive-disease small-cell lung cancer.

Methods: In this randomized, double-blind study, unselected patients with previously untreated ED-SCLC received roniciclib 5 mg or placebo twice daily in a 3 days on/4 day off schedule in 21-day cycles, with concomitant cisplatin or carboplatin on day 1, and etoposide on days 1-3. The primary endpoint was progression-free survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.010DOI Listing
January 2019
2 Reads

The relationship between air pollution and lung cancer in non-smokers in Taiwan.

J Thorac Oncol 2019 Jan 18. Epub 2019 Jan 18.

Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Comprehensive Cancer Center, Taichung Veterans General Hospital, Taichung, Taiwan. Electronic address:

Introduction: For never-smokers (smoked <100 lifetime cigarettes), lung cancer (LC) has emerged as an important issue. We aimed to investigate the effects of prevalence changes in tobacco smoking and particulate matter (PM) 2.5 (PM) levels on LC in Taiwan, in relation to contrasting PM levels, between northern Taiwan (NT) and southern Taiwan (ST). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193002
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.12.033DOI Listing
January 2019
7 Reads

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC.

J Thorac Oncol 2019 Jan 18. Epub 2019 Jan 18.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

Introduction: Circulating tumor DNA analysis is an emerging genotyping strategy that can identify tumor-specific genetic alterations in plasma including mutations and rearrangements. Detection of ROS1 fusions in plasma requires genotyping approaches that cover multiple breakpoints and target a variety of fusion partners. Compared to other molecular subsets of NSCLC, experience with detecting ROS1 genetic alterations in plasma is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.009DOI Listing
January 2019
2 Reads

A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial.

J Thorac Oncol 2019 Jan 18. Epub 2019 Jan 18.

Service de pneumologie aiguë spécialisée et cancérologie thoracique. Centre hospitalier Lyon Sud. 165 Chemin du Grand Revoyet; 69495 PIERRE-BENITE.

Introduction: This randomized phase 2 trial aimed at evaluating the engineered programmed cell death-ligand 1 (PD-L1) antibody atezolizumab in small cell lung cancer progressing after first-line platinum-etoposide chemotherapy.

Methods: Patients were randomized 2:1 to atezolizumab (1200mg intravenously every 3 weeks) until progression or unacceptable toxicity, or conventional chemotherapy (up to six cycles of topotecan or re-induction of initial chemotherapy). Patients were not selected based on PD-L1 tissue expression. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193002
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.01.008DOI Listing
January 2019
7 Reads

Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History.

J Thorac Oncol 2019 Jan 18. Epub 2019 Jan 18.

Massachusetts General Hospital, Center for Integrated Diagnostics, Boston, Massachusetts.

Introduction: Lung cancer patients with tumors harboring actionable alterations can achieve very durable responses to first-line targeted therapy. However, identifying targetable alterations using next-generation sequencing (NGS) is a complex and time-intensive process. As actionable genetic alterations are enriched in lung cancers arising in patients with limited smoking history, we designed a workflow to expedite NGS testing for this group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.032DOI Listing
January 2019

Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.

J Thorac Oncol 2019 Jan 17. Epub 2019 Jan 17.

Guangdong General Hospital, School of Medicine, South China University of Technology, Guangzhou, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address:

Introduction: Leptomeningeal metastases (LMs) indicated a poor prognosis in NSCLC. LMs were more frequent in driver gene-mutated patients, and cerebrospinal fluid (CSF) cell-free DNA has shown unique genetic profiles of LM in EGFR-mutated LM. However, studies in patients with ALK receptor tyrosine kinase gene (ALK)-rearranged NSCLC with LMs are scarce. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.01.007DOI Listing
January 2019
2 Reads
5.282 Impact Factor

Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype.

J Thorac Oncol 2019 Jan 17. Epub 2019 Jan 17.

Department of Thoracic Surgery, Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; School of Life Sciences, Fudan University, Shanghai, People's Republic of China; Institutes of Biomedical Sciences, Fudan University, Shanghai, China. Electronic address:

Introduction: The clinicopathologic features and prognostic predictors of radiological part-solid lung adenocarcinomas were unclear.

Methods: We retrospectively compared the clinicopathologic features and survival times of part-solid tumors with those of pure ground glass nodules (pGGNs) and pure solid tumors treated with surgery at Fudan University Shanghai Cancer Center and evaluated the prognostic implications of consolidation-to-tumor ratio (CTR), solid component size, and tumor size for part-solid lung adenocarcinomas.

Results: A total of 911 patients and 988 pulmonary nodules (including 329 part-solid nodules [PSNs], 501 pGGNs, and 158 pure solid nodules) were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.030DOI Listing
January 2019
1 Read
5.282 Impact Factor